Am J Psychiatry 1976; 133:80-82
Copyright © 1976 by American Psychiatric Association
Antiparkinsonian agents and fluphenazine decanoate
S Idzorek
The author examined the incidence and severity of extrapyramidal symptoms
(EPS) in 19 male psychotic outpatients receiving fluphenazine decanoate.
Ten patients developed an EPS; only 3 had symptoms of the highest severity.
The data suggest that neither prophylactic nor long- term use of
antiparkinsonian agents is necessary for most patients receiving
fluphenazine decanoate. On the basis of a comparison to a study of
fluphenazine enanthate patients, the author concludes that fluphenazine
decanoate is the drug of choice in terms of incidence and severity of EPS.
